| Zacks Company Profile for Tengion Inc. (TNGNQ : OTC) |
|
|
| |
| • Company Description |
| Tengion, Inc. is a clinical-stage biotechnology company, focused on discovering, developing, manufacturing and commercializing a range of replacement neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company creates these functional neo-organs and neo-tissues using a patient's autologous cells, in conjunction with its Organ Regeneration Platform. Tengion's lead product candidate, the Neo-Urinary Conduit, is an autologous implant that catalyzes regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal, or cystectomy. Its product pipeline also includes various candidates in early stage development, such as Neo-Kidney Augment for patients with advanced chronic kidney disease, or CKD. The Company intends to develop our technology to address unmet medical needs in urologic, renal, gastrointestinal and vascular diseases. Tengion, Inc. is headquartered in East Norriton, Pennsylvania.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: |
| 52 Week High: $ |
| 52 Week Low: $ |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
% |
% |
| 12 Week |
% |
% |
| Year To Date |
% |
% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
3929 WESTPOINT BLVD. SUITE G
-
WINSTON-SALEM,NC 27103
USA |
ph: 336-722-5855
fax: - |
ir@tengion.com |
http://www.tengion.com |
|
|
| |
| • General Corporate Information |
Officers
David I. Scheer - Chairman
John L. Miclot - President and Chief Executive Officer
A. Brian Davis - Chief Financial Officer and Senior Vice President
Carl-Johan Dalsgaard - Director
Diane K. Jorkasky - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 88034G208
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 6.00 (0.10:1)
Beta:
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
